86801-04-9

Basic information

• Product Name: 1-(3-ACETYLPHENYL)-2-THIOUREA
• Synonyms: 3-ACETYLPHENYLTHIOUREA;1-(3-ACETYLPHENYL)-2-THIOUREA;3'-(Carbamothioylamino)acetophenone;3'-(Carbamothioylamino)acetophenone, 3'-Thioureidoacetophenone
• CAS NO: 86801-04-9
• Molecular Formula: C₉H₁₀N₂OS
• Molecular Weight: 194.25
• Mol File: 86801-04-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 165-167°C
• Boiling Point: 347.8 °C at 760 mmHg
• Flash Point: 164.1 °C
• Appearance: /
• Density: 1.302 g/cm³
• Vapor Pressure: 5.25E-05mmHg at 25°C
• Refractive Index: 1.685
• PKA: 12.54±0.70(Predicted)
• CAS DataBase Reference: 1-(3-ACETYLPHENYL)-2-THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-ACETYLPHENYL)-2-THIOUREA(86801-04-9)
• EPA Substance Registry System: 1-(3-ACETYLPHENYL)-2-THIOUREA(86801-04-9)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 86801-04-9(Hazardous Substances Data)

Usage

Description

1-(3-Acetylphenyl)-2-thiourea is an organic compound with the chemical formula C9H10N2S. It is a derivative of thiourea, which is a sulfur-containing compound known for its diverse applications in various fields. This specific compound features a 3-acetylphenyl group attached to the thiourea core, which may contribute to its unique properties and potential uses.

Uses

Used in Pharmaceutical Research:
1-(3-Acetylphenyl)-2-thiourea is used as a research reagent for the synthesis of 2-(3-acylphenyl)amino-4-phenylthiazoles, which possess antibacterial activity. These synthesized compounds can be further explored and developed for potential applications in the pharmaceutical industry, particularly for the treatment of bacterial infections.
Used in Chemical Synthesis:
In the field of organic chemistry, 1-(3-Acetylphenyl)-2-thiourea can be utilized as an intermediate or building block in the synthesis of various organic compounds. Its unique structure allows for the formation of new chemical entities with potential applications in different industries, such as pharmaceuticals, agrochemicals, or materials science.

InChI:InChI=1/C9H10N2OS/c1-6(12)7-3-2-4-8(5-7)11-9(10)13/h2-5H,1H3,(H3,10,11,13)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 99-03-6 1-(3-aminophenyl)ethanone 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 116433-38-6 C₃₄H₃₂N₆O₆S₃ 
• 315703-08-3 1-(3-{[4-(4-pyridinyl)-1,3-thiazol-2-yl]amino}phenyl)ethanone 
• 315706-16-2 C₁₇H₁₃ClN₂OS 

Relevant articles and documents

Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases

Enteroviruses (EVs) are among the most frequent infectious agents in humans worldwide and represent the leading cause of upper respiratory tract infections. No drugs for the treatment of EV infections are currently available. Recent studies have also linked EV infection with pulmonary exacerbations, especially in cystic fibrosis (CF) patients, and the importance of this link is probably underestimated. The aim of this work was to develop a new class of multitarget agents active both as broad-spectrum antivirals and as correctors of the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding defect responsible for >90% of CF cases. We report herein the discovery of the first small molecules able to simultaneously act as correctors of the F508del-CFTR folding defect and as broad-spectrum antivirals against a panel of EVs representative of all major species.

HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT

Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.